K N Slaughter Wade1, M F Brady2, T Thai3, Y Wang4, B Zheng5, R Salani6, K S Tewari7, H J Gray8, J N Bakkum-Gamez9, R A Burger10, K N Moore11, M A Bookman12. 1. The University of Oklahoma, Oklahoma City, OK, USA. Electronic address: Katrina.wade@ochsner.org. 2. NRG Oncology Statistical and Data Center, Roswell Park Cancer Institute, University of Buffalo, Buffalo, NY, USA. Electronic address: BradyM@NRGOncology.org. 3. The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: Theresa-thai@ouhsc.edu. 4. The University of Oklahoma, Norman, OK, USA. Electronic address: Yunzhi.Wang-1@ou.edu. 5. The University of Oklahoma, Norman, OK, USA. Electronic address: bin.Zheng-1@ou.edu. 6. The Ohio State University, James Cancer Hospital, Columbus, OH, USA. Electronic address: ritu.salani@osumc.edu. 7. UC Irvine Medical Center, Orange, CA, USA. Electronic address: ktewari@uci.edu. 8. University of Washington Medical Center, Seattle, WA, USA. Electronic address: hgray@uw.edu. 9. Mayo Clinic, Rochester, MN, USA. Electronic address: bakkum.jamie@mayo.edu. 10. University of Pennsylvania, Philadelphia, PA, USA. Electronic address: burgerr@uphs.upenn.edu. 11. The University of Oklahoma, Oklahoma City, OK, USA. Electronic address: Kathleen-moore@ouhsc.edu. 12. US Oncology Research and Arizona Oncology, Tucson, AZ, USA. Electronic address: Michael.a.bookman@kp.org.
Abstract
OBJECTIVE:Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. METHOD:Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to eitherchemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. RESULTS: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). CONCLUSION: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
RCT Entities:
OBJECTIVE: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. METHOD: Pretreatment computed tomography (CT) for 1538 GOG 218participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. RESULTS: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). CONCLUSION: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
Authors: T Yoshizumi; T Nakamura; M Yamane; A H Islam; M Menju; K Yamasaki; T Arai; K Kotani; T Funahashi; S Yamashita; Y Matsuzawa Journal: Radiology Date: 1999-04 Impact factor: 11.105
Authors: Whalen Clark; Erin M Siegel; Y Ann Chen; Xiuhua Zhao; Colin M Parsons; Jonathan M Hernandez; Jill Weber; Shalini Thareja; Junsung Choi; David Shibata Journal: J Am Coll Surg Date: 2013-03-21 Impact factor: 6.113
Authors: Stephanie Stelten; Christelle Schofield; Yvonne A W Hartman; Pedro Lopez; Gemma G Kenter; Robert U Newton; Daniel A Galvão; Meeke Hoedjes; Dennis R Taaffe; Luc R C W van Lonkhuijzen; Carolyn McIntyre; Laurien M Buffart Journal: Cancers (Basel) Date: 2022-09-20 Impact factor: 6.575